Alzecure Q1 Update: Inflection point ahead - Redeye

Redeye returns with an update following the Q1 report. We continue to believe that the current valuation of the company is undemanding and that important inflection points are ahead, most notably the phase II readout in pain with ACD440 this summer.

Länk till analysen i sin helhet: https://www.redeye.se/research/903132/alzecure-q1-update-inflection-point-ahead?utm_source=finwire&utm_medium=RSS